Spyglass Pharma, Inc. (NASDAQ:SGP) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Spyglass Pharma, Inc. (NASDAQ:SGP - Get Free Report) has earned a consensus rating of "Moderate Buy" from the five brokerages that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $47.00.Get Spyglass Pharma alerts:Several research firms have commented on SGP. Leerink Partners downgraded shares of Spyglass Pharma to a "market perform" rating in a research report on Tuesday. Zacks Research raised Spyglass Pharma to a "hold" rating in a research report on Wednesday. Citigroup initiated coverage on Spyglass Pharma in a report on Tuesday. They set a "buy" rating and a $42.00 price objective on the stock. Wall Street Zen raised Spyglass Pharma to a "hold" rating in a research note on Tuesday, February 17th. Finally, Stifel Nicolaus started coverage on Spyglass Pharma in a report on Tuesday. They issued a "buy" rating and a $42.00 target price for the company.Check Out Our Latest Research Report on Spyglass PharmaInsider Buying and Selling at Spyglass PharmaIn other news, Director Ra Capital Management, L.P. acquired 3,690,000 shares of Spyglass Pharma stock in a transaction dated Monday, February 9th. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $59,040,000.00. Following the completion of the purchase, the director owned 5,966,439 shares of the company's stock, valued at $95,463,024. This represents a 162.10% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Spyglass Pharma Trading Down 1.0%Shares of SGP opened at $26.42 on Friday. Spyglass Pharma has a 12 month low of $20.16 and a 12 month high of $32.44. About Spyglass Pharma (Get Free Report)We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. Our lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary drug pads attached to our intraocular lens (IOL), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT).See AlsoFive stocks we like better than Spyglass PharmaSilver Is the New Oil—And the World’s Running DryBNZI stands out as a Zacks Buy. Earnings momentum and analyst upgrades align1,500 Banks Just Handed the Fed Your Bank AccountElon Musk’s $1 Quadrillion AI IPO[How To] Invest Pre-IPO In SpaceX With $100!This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Spyglass Pharma Right Now?Before you consider Spyglass Pharma, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spyglass Pharma wasn't on the list.While Spyglass Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here